ClinicalTrials.gg
CompletedNCT00195702Updated Aug 26, 2011Results posted

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

A Phase 3 interventional study of Adalimumab and Adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 87 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-26.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
619
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
15th of 87
619 · median 160
Started
2000
with 3 others
Phase 3
36 of 87
1 open now
Registered
2nd of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 15th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.

Read the detailed description

This was a 10-year study which had an initial 52-week, double-blind, placebo-controlled phase followed by an open-label extension phase up to 9 years in duration. Data were analyzed for the double-blind phase using all patients who were randomized and received at least one dose of study drug through Week 52 and for all patients who received at least one dose of adalimumab during the 10-year study (the Intent-to-Treat [ITT] population).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older and in good health (Investigator discretion) with a recent stable medical history
  • Met American College of Rheumatology (ACR) criteria for diagnosis of active rheumatoid arthritis (RA) and had at both screening and baseline visits >=6 swollen joints and >=9 tender joints, despite a minimum of 3-months treatment with methotrexate (MTX). (Distal interphalangeal joints [DIPs] were not to be included in joint count for inclusion. The screening and baseline visits could be 3 to 28 days apart for patients not previously receiving disease-modifying anti-rheumatic drugs [DMARDs] other than MTX or 4 to 6 weeks for patients requiring a DMARD .)
  • Insufficient efficacy with MTX 12.5 to 25 mg per week (10 mg per week if MTX intolerant).
  • If patient on a treatment (DMARD) other than MTX, he/she had to discontinue it for at least 28 days before the baseline visit (the washout period).
  • Treatment with oral folic acid 1-3 mg/day or, if appropriate, up to 10 mg leucovorin per week.
  • Both rheumatoid factor positivity and a C-reactive protein value >=1 mg/dL, or at least one joint erosion on X-ray.

Exclusion criteria

Exclusion Criteria:

  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study.
  • Female subject who was pregnant or breast-feeding or considering becoming pregnant.
  • Preceding treatment with any tumor necrosis factor (TNF) antagonist, including adalimumab.
  • Prior exposure to alkylating agents, such as chlorambucil or cyclophosphamide.
  • Intra-articular, intramuscular, or intravenous administration of within 4 weeks prior to the screening visit.
  • Subject was wheelchair bound or bedridden.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
619 participants (actual)

Study arms

  • Experimental
    DB adalimumab 20 mg ew

    Subjects received 20 mg adalimumab subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.

    Biological: Adalimumab

  • Experimental
    DB adalimumab 40 mg eow

    Subjects received 40 mg adalimumab subcutaneously (SC) every other week (eow) and concomitant methotrexate (MTX) during the double-blind (DB) phase. Subjects received placebo injections SC and concomitant MTX on the alternate weeks during the DB phase.

    Biological: Adalimumab

  • Placebo comparator
    DB placebo ew

    Subjects received placebo subcutaneously (SC) once weekly (ew) and concomitant methotrexate (MTX) during the double-blind (DB) phase.

    Drug: Placebo

  • Experimental
    DB adalimumab 20 mg ew/OL adalimumab 40 mg eow

    Subjects received adalimumab 20 mg subcutaneously (SC) once weekly (ew) during the double-blind (DB) phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).

    Biological: Adalimumab

  • Experimental
    DB adalimumab 40 mg eow/OL adalimumab 40 mg eow

    Subjects received adalimumab 40 mg subcutaneously (SC) every other week (eow) with placebo on alternate weeks during the double-blind (DB) phase, then adalimumab 40 mg SC eow during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).

    Biological: Adalimumab

  • Experimental
    DB placebo ew/OL adalimumab 40 mg eow

    Subjects received placebo subcutaneously (SC) once weekly (ew) during the double-blind phase, then adalimumab 40 mg SC every other week (eow) during the open-label (OL) extension phase, along with concomitant methotrexate (MTX).

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.

    Also known as: ABT-D2E7, Humira

  • BiologicalAdalimumab

    Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.

    Also known as: ABT-D2E7, Humira

  • DrugPlacebo

    Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.

  • BiologicalAdalimumab

    Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.

    Also known as: ABT-D2E7, Humira

  • BiologicalAdalimumab

    Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.

    Also known as: ABT-D2E7, Humira

  • BiologicalAdalimumab

    Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.

    Also known as: ABT-D2E7, Humira

06

What researchers measure

Primary outcomes

  1. Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Week 24

  2. Change From Baseline in Modified Total Sharp X-ray Score at Week 52

    Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 52. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

    Time frame: Baseline and Week 52

  3. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52

    Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Number of Participants Meeting ACR20 Response Criteria at Week 52

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Week 52

  2. Change From Baseline in Modified Total Sharp X-ray Score at Week 24

    Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 24. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

    Time frame: Baseline and Week 24

  3. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24

    Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.

    Time frame: Baseline and Week 24

  4. Maintenance of the Disability Index of the HAQ at Week 52 for Participants Who Were Responders at Week 12 or Week 24

    Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Responders had a \>= 0.22-unit decrease (improvement) in HAQ scores from baseline to Week 12 or 24.

    Time frame: Week 52

  5. Maintenance of ACR20 Response at Week 52 for Participants Who Were ACR20 Responders at Week 24

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Week 52

  6. Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment

    Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Baseline through Week 52

  7. Time to First Response According to ACR20 Criteria - Number of Participants Meeting ACR20 Criteria for the First Time at Each Time Point

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Baseline through Week 52

  8. Time to First Response According to ACR50 Criteria - Number of Participants Meeting ACR50 Criteria for the First Time at Each Time Point

    Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Baseline through Week 52

  9. Time to First Response According to ACR70 Criteria - Number of Participants Meeting ACR70 Criteria for the First Time at Each Time Point

    Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

    Time frame: Baseline through Week 52

  10. Estimated Yearly Progression of Rheumatoid Arthritis

    Estimated yearly progression was defined as modified total Sharp x-ray score at baseline divided by duration of rheumatoid arthritis disease at baseline. Actual progression during the study was defined as modified total Sharp x-ray score at Week 52 minus modified total Sharp x-ray score at baseline divided by the duration of the study. The range of scores for the modified total Sharp x-ray score was 0 (normal) to 398 (maximal disease).

    Time frame: Baseline and Week 52

Other outcomes

  1. Baseline Measure: Gender - Female/Male - for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)

    Gender (female/male) recorded at Baseline for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.

    Time frame: Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group

  2. Baseline Measure: Age Categories for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)

    Age recorded at Baseline, reported by category, for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.

    Time frame: Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group

  3. Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 260

  4. Number of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520

    Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 520

  5. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260

    Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 260

  6. Number of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520

    Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 520

  7. Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 260

    Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 260

  8. Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 520

    Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Week 520

  9. Number of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10

    Patients were responders if they had: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

    Time frame: Baseline through Week 520

  10. Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260

    The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.

    Time frame: Week 260

  11. Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520

    The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.

    Time frame: Week 520

  12. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260

    Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.

    Time frame: Baseline and Week 260

  13. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520

    Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.

    Time frame: Baseline and Week 520

  14. Change From Baseline in Modified Total Sharp X-ray Score at Week 416

    Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 416. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

    Time frame: Baseline and Week 416

  15. Change From Baseline in Modified Total Sharp X-ray Score at Week 520

    Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 520. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

    Time frame: Baseline and Week 520

07

Results

Posted Mar 1, 2010

Participant flow

Subjects were enrolled at 95 sites in the United States and Canada between February 2000 and August 2001.

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewDB Adalimumab 20 mg ew/OL Adalimumab 40 mg EowDB Adalimumab 40 mg Eow/OL Adalimumab 40 mg EowDB Placebo ew/OL Adalimumab 40 mg Eow
Started212207200000
Completed168159140000
Not completed444860000
Open-label Extension Phase
Participant flow — Open-label Extension Phase
MilestoneDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewDB Adalimumab 20 mg ew/OL Adalimumab 40 mg EowDB Adalimumab 40 mg Eow/OL Adalimumab 40 mg EowDB Placebo ew/OL Adalimumab 40 mg Eow
Started000165158134
Completed000668056
Not completed000997878

Outcome measures

PrimaryNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 2412913159
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · Chi-squared · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · Chi-squared · p = <0.001
PrimaryChange From Baseline in Modified Total Sharp X-ray Score at Week 52

Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 52. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Total Sharp X-ray Score at Week 52
Units on a scaleDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Change From Baseline in Modified Total Sharp X-ray Score at Week 520.8 ± 4.90.1 ± 4.82.7 ± 6.8
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · ANCOVA · p = <0.001 (An ANCOVA model with baseline erosion scores as the covariate was performed. An overall significance test at alpha =0.05 was done. Pairwise comparisons, each at alpha =0.05 (2-sided), were performed if the overall test was significant.)
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · ANCOVA · p = <0.001 (An ANCOVA model with baseline erosion scores as the covariate was performed. An overall significance test at alpha =0.05 was done. Pairwise comparisons, each at alpha =0.05 (2-sided), were performed if the overall test was significant.)
SecondaryNumber of Participants Meeting ACR20 Response Criteria at Week 52

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Week 52
Reported as:
Number · Participants
Number of Participants Meeting ACR20 Response Criteria at Week 52
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Number of Participants Meeting ACR20 Response Criteria at Week 5211612248
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · Chi-squared · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · Chi-squared · p = <0.001
SecondaryChange From Baseline in Modified Total Sharp X-ray Score at Week 24

Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 24. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

Time frame:
Baseline and Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in Modified Total Sharp X-ray Score at Week 24
Units on a scaleDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Change From Baseline in Modified Total Sharp X-ray Score at Week 240.6 ± 4.90.3 ± 4.51.3 ± 3.7
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · ANCOVA · p = <0.01
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · ANCOVA · p = <0.001
SecondaryChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24

Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.

Time frame:
Baseline and Week 24
Reported as:
Mean · Units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24
Units on a scaleDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 24-0.60 ± 0.53-0.56 ± 0.52-0.24 ± 0.52
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · ANCOVA · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · ANCOVA · p = <0.001
PrimaryChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52

Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from baseline in the disability index of the HAQ indicated improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52
Units on a scaleDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52-0.61 ± 0.55-0.59 ± 0.57-0.25 ± 0.56
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · ANCOVA · p = <0.001 (Normality was evaluated by applying the Shapiro-Wilk test to residuals from the parametric model. The final analysis was performed using a parametric approach.)
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · ANCOVA · p = <0.001 (Normality was evaluated by applying the Shapiro-Wilk test to residuals from the parametric model. The final analysis was performed using a parametric approach.)
SecondaryMaintenance of the Disability Index of the HAQ at Week 52 for Participants Who Were Responders at Week 12 or Week 24

Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3) eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Responders had a \>= 0.22-unit decrease (improvement) in HAQ scores from baseline to Week 12 or 24.

Time frame:
Week 52
Reported as:
Number · Participants
Maintenance of the Disability Index of the HAQ at Week 52 for Participants Who Were Responders at Week 12 or Week 24
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Maintained Response13012173
Did Not Maintain Response749
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · Chi-squared · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · Chi-squared · p = <0.001
SecondaryMaintenance of ACR20 Response at Week 52 for Participants Who Were ACR20 Responders at Week 24

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Week 52
Reported as:
Number · Participants
Maintenance of ACR20 Response at Week 52 for Participants Who Were ACR20 Responders at Week 24
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Maintained Response9911132
Did Not Maintain Response211223
Missing984
SecondaryNumber of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment

Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Baseline through Week 52
Reported as:
Number · Participants
Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Number of Participants With a Continuous ACR70 Response for 6 Months During 52 Weeks of Treatment20183
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · Chi-squared · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · Chi-squared · p = <0.001
SecondaryTime to First Response According to ACR20 Criteria - Number of Participants Meeting ACR20 Criteria for the First Time at Each Time Point

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Baseline through Week 52
Reported as:
Number · Participants
Time to First Response According to ACR20 Criteria - Number of Participants Meeting ACR20 Criteria for the First Time at Each Time Point
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Non-responder252981
Week 2695326
Week 4484830
Week 8293321
Week 12172314
Week 167812
Week 20873
Week 24227
Week 32422
Week 40021
Week 48102
Week 52201
SecondaryTime to First Response According to ACR50 Criteria - Number of Participants Meeting ACR50 Criteria for the First Time at Each Time Point

Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Baseline through Week 52
Reported as:
Number · Participants
Time to First Response According to ACR50 Criteria - Number of Participants Meeting ACR50 Criteria for the First Time at Each Time Point
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Non-responder7169135
Week 218134
Week 417266
Week 826256
Week 12252110
Week 1623218
Week 2016109
Week 24773
Week 32478
Week 40326
Week 48133
Week 52132
SecondaryTime to First Response According to ACR70 Criteria - Number of Participants Meeting ACR70 Criteria for the First Time at Each Time Point

Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein. Patients withdrawing early or receiving additional disease-modifying anti-rheumatic drugs (DMARDs) after Week 16 were non-responders.

Time frame:
Baseline through Week 52
Reported as:
Number · Participants
Time to First Response According to ACR70 Criteria - Number of Participants Meeting ACR70 Criteria for the First Time at Each Time Point
ParticipantsDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Non-responder126120177
Week 2552
Week 4563
Week 81171
Week 1214162
Week 161591
Week 209112
Week 244112
Week 32983
Week 40442
Week 48463
Week 52642
SecondaryEstimated Yearly Progression of Rheumatoid Arthritis

Estimated yearly progression was defined as modified total Sharp x-ray score at baseline divided by duration of rheumatoid arthritis disease at baseline. Actual progression during the study was defined as modified total Sharp x-ray score at Week 52 minus modified total Sharp x-ray score at baseline divided by the duration of the study. The range of scores for the modified total Sharp x-ray score was 0 (normal) to 398 (maximal disease).

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
Estimated Yearly Progression of Rheumatoid Arthritis
Units on a scaleDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ew
Estimated yearly progression11.11 ± 16.759.46 ± 10.429.97 ± 12.84
Actual progression during study0.77 ± 4.900.09 ± 4.752.66 ± 6.73
Statistical analysis
  • DB Adalimumab 20 mg ew vs DB Placebo ew · ANCOVA · p = <0.001
  • DB Adalimumab 40 mg Eow vs DB Placebo ew · ANCOVA · p = <0.001
Other pre-specifiedBaseline Measure: Gender - Female/Male - for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)

Gender (female/male) recorded at Baseline for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.

Time frame:
Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group
Reported as:
Number · participants
Baseline Measure: Gender - Female/Male - for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)
participantsAny Adalimumab Through Year 10
Female413
Male140
Other pre-specifiedBaseline Measure: Age Categories for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)

Age recorded at Baseline, reported by category, for the Intent-to-Treat population (the Any Adalimumab Through Year 10 group) of the study. This measure was not included in the Baseline Characteristics section due to the difficulty of maintaining correct subject numbers and totals in that section.

Time frame:
Baseline for Intent-to-Treat (Any Adalimumab Through Year 10) Group
Reported as:
Number · participants
Baseline Measure: Age Categories for the Any Adalimumab Through Year 10 Group (Intent-to-Treat)
participantsAny Adalimumab Through Year 10
< 40 years50
Between 40 and 64 years361
Between 65 and 74 years117
>= 75 years25
Other pre-specifiedNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 260
Reported as:
Number · Participants
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260
ParticipantsAny Adalimumab Through Year 10
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260200
Other pre-specifiedNumber of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520

Patients were responders if they had: \>= 20% improvement in tender joint count; \>= 20% improvement in swollen joint count; and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520
participantsAny Adalimumab Through Year 10
Number of Participants Meeting the American College of Rheumatology 20% (ACR20) Response Criteria at Week 520115
Other pre-specifiedNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260

Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260
participantsAny Adalimumab Through Year 10
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260153
Other pre-specifiedNumber of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520

Patients were responders if they had: \>= 50% improvement in tender joint count; \>= 50% improvement in swollen joint count; and \>= 50% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520
participantsAny Adalimumab Through Year 10
Number of Participants Meeting the American College of Rheumatology 50% (ACR50) Response Criteria at Week 520100
Other pre-specifiedNumber of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 260

Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 260
participantsAny Adalimumab Through Year 10
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 26087
Other pre-specifiedNumber of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 520

Patients were responders if they had: \>= 70% improvement in tender joint count; \>= 70% improvement in swollen joint count; and \>= 70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 520
participantsAny Adalimumab Through Year 10
Number of Participants Meeting the American College of Rheumatology 70% (ACR70) Response Criteria at Week 52078
Other pre-specifiedNumber of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10

Patients were responders if they had: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and acute phase reactant: C-reactive protein.

Time frame:
Baseline through Week 520
Reported as:
Number · participants
Number of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10
participantsAny Adalimumab Through Year 10
Number of Participants With a Continuous American College of Rheumatology 70% (ACR70) Response for at Least 6 Months Through Year 10159
Other pre-specifiedNumber of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260

The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260
participantsAny Adalimumab Through Year 10
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 260205
Other pre-specifiedNumber of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520

The Health Assessment Questionnaire (HAQ) Disability Index is a self-reported measure of disability, which assesses the patient's ability to perform the following tasks: dress and groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity. Possible responses/scores are 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). Negative mean changes from Baseline indicate improvement. An improvement of 0.22 in score (a -0.22 or greater reduction from Baseline score) is a minimally clinically significant change.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520
participantsAny Adalimumab Through Year 10
Number of Participants With at Least a 0.22 Reduction From Baseline in the Health Assessment Questionnaire (HAQ) Disability Index at Week 520110
Other pre-specifiedChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260

Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.

Time frame:
Baseline and Week 260
Reported as:
Mean · units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260
units on a scaleAny Adalimumab Through Year 10
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260-0.56 ± 0.62
Other pre-specifiedChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520

Subjects assessed their ability to perform the following tasks: 1) dress/groom; 2) arise; 3)eat; 4) walk; 5) reach; 6) grip; 7) maintain hygiene; and 8) maintain daily activity. Subjects assessed their ability to do these tasks over the past week by marking their response on a questionnaire. Possible responses/scores were: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Negative mean changes from Baseline in the disability index of the HAQ indicated improvement.

Time frame:
Baseline and Week 520
Reported as:
Mean · units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520
units on a scaleAny Adalimumab Through Year 10
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520-0.62 ± 0.60
Other pre-specifiedChange From Baseline in Modified Total Sharp X-ray Score at Week 416

Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 416. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

Time frame:
Baseline and Week 416
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp X-ray Score at Week 416
units on a scaleDB Adalimumab 20 mg ew/OL Adalimumab 40 mg EowDB Adalimumab 40 mg Eow/OL Adalimumab 40 mg EowDB Placebo ew/OL Adalimumab 40 mg Eow
Change From Baseline in Modified Total Sharp X-ray Score at Week 4161.16 ± 7.9690.14 ± 9.3104.83 ± 10.012
Other pre-specifiedChange From Baseline in Modified Total Sharp X-ray Score at Week 520

Modified total Sharp x-ray score (mTSS) is a measure of change in joint health. Radiographs of hands/wrists and feet were obtained at screening and Week 520. Digitized images of these were scored in a blinded manner. Joints were scored for erosions from 0 (no damage) to 5 and for joint space narrowing from 0 (no damage) to 4; scores were added to obtain the mTSS (range = 0 \[normal\] to 398 \[maximal disease\]). Large positive change indicates disease progression; small positive/no change indicates slowing/halting of disease progression; and negative change may indicate improvement of disease.

Time frame:
Baseline and Week 520
Reported as:
Mean · units on a scale
Change From Baseline in Modified Total Sharp X-ray Score at Week 520
units on a scaleDB Adalimumab 20 mg ew/OL Adalimumab 40 mg EowDB Adalimumab 40 mg Eow/OL Adalimumab 40 mg EowDB Placebo ew/OL Adalimumab 40 mg Eow
Change From Baseline in Modified Total Sharp X-ray Score at Week 5202.60 ± 8.8220.72 ± 10.4306.18 ± 12.071

Adverse events

Collected over For the double-blind (DB) phase: Week 0 to Week 52; for the Any Adalimumab Through Year 10 (intent-to-treat [ITT]) group: first adalimumab injection to the last day in Year 10 (for each subject, the day of the last adalimumab injection plus 70 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Adalimumab 20 mg ew—34/212 (16%)167/212 (78.8%)
DB Adalimumab 40 mg Eow—27/207 (13%)148/207 (71.5%)
DB Placebo ew—20/200 (10%)149/200 (74.5%)
Any Adalimumab Through Year 10—271/553 (49%)511/553 (92.4%)
Most frequent serious events
Showing 10 of 340
Most frequent serious events
EventDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewAny Adalimumab Through Year 10
Rheumatoid arthritisMusculoskeletal and connective tissue disorders2/2120/2071/20035/553
PneumoniaInfections and infestations1/2124/2071/20020/553
OsteoarthritisMusculoskeletal and connective tissue disorders0/2120/2070/20018/553
CellulitisInfections and infestations0/2120/2070/20015/553
ArthralgiaMusculoskeletal and connective tissue disorders1/2120/2070/20013/553
Myocardial infarctionCardiac disorders0/2121/2070/20010/553
Atrial fibrillationCardiac disorders1/2121/2071/2007/553
Coronary artery diseaseCardiac disorders0/2121/2070/2007/553
Hip fractureInjury, poisoning and procedural complications0/2121/2070/2007/553
Lobar pneumoniaInfections and infestations0/2120/2070/2007/553
Most frequent other events
Showing 10 of 64
Most frequent other events
EventDB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewAny Adalimumab Through Year 10
Upper respiratory tract infectionInfections and infestations35/21235/20722/200225/553
SinusitisInfections and infestations21/21222/20717/200150/553
Rheumatoid arthritisMusculoskeletal and connective tissue disorders10/21214/20724/200123/553
ArthralgiaMusculoskeletal and connective tissue disorders19/21211/20715/200120/553
NasopharyngitisInfections and infestations23/21224/20718/200119/553
Injection site painGeneral disorders37/21237/20743/20074/553
Urinary tract infectionInfections and infestations16/21218/20715/200118/553
HypertensionVascular disorders11/2129/2074/200116/553
BronchitisInfections and infestations16/2127/20715/200106/553
Back painMusculoskeletal and connective tissue disorders15/21210/2079/200103/553

Baseline characteristics

Age, Customized
Age, Customized(participants)DB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewTotal
< 40 years10271855
Between 40 and 64 years150115137402
Between 65 and 74 years415435130
>= 75 years11111032
Sex: Female, Male
Sex: Female, Male(Participants)DB Adalimumab 20 mg ewDB Adalimumab 40 mg EowDB Placebo ewTotal
Female160158146464
Male524954155
08

Study locations

87 sites
  • Site Ref # / Investigator 424
    Huntsville, Alabama 35801, United States
  • Site Ref # / Investigator 2510
    Mobile, Alabama 36608, United States
  • Site Ref # / Investigator 60729
    Phoenix, Arizona 85012, United States
  • Site Ref # / Investigator 725
    Scottsdale, Arizona 85260, United States
  • Site Ref # / Investigator 60736
    Anaheim, California 92801, United States
  • Site Ref # / Investigator 360
    Escondido, California 92025, United States
  • Site Ref # / Investigator 714
    La Jolla, California 92037-0943, United States
  • Site Ref # / Investigator 469
    La Jolla, California 92037, United States
  • Site Ref # / Investigator 419
    Palm Desert, California 92260, United States
  • Site Ref # / Investigator 492
    San Jose, California 95126, United States
  • Site Ref # / Investigator 60734
    San Louis Obispo, California 93405, United States
  • Site Ref # / Investigator 60739
    Van Nuys, California 91405, United States
  • Site Ref # / Investigator 712
    Danbury, Connecticut 06810, United States
  • Site Ref # / Investigator 710
    Aventura, Florida 33180, United States
  • Site Ref # / Investigator 498
    Dunedin, Florida 34698, United States
  • Site Ref # / Investigator 499
    Orlando, Florida 32806, United States
  • Site Ref # / Investigator 729
    Tampa, Florida 33614, United States
  • Site Ref # / Investigator 463
    Zephyrhills, Florida 33542, United States
  • Site Ref # / Investigator 2436
    Boise, Idaho 83704, United States
  • Site Ref # / Investigator 485
    Idaho Falls, Idaho 83404, United States
  • Site Ref # / Investigator 60732
    Chicago, Illinois 60611, United States
  • Site Ref # / Investigator 726
    Springfield, Illinois 62704, United States
  • Site Ref # / Investigator 2506
    Indianapolis, Indiana 46260, United States
  • Site Ref # / Investigator 732
    South Bend, Indiana 46601, United States
  • Site Ref # / Investigator 60730
    Shawnee Mission, Kansas 66216, United States
  • Site Ref # / Investigator 467
    Wichita, Kansas 67203, United States
  • Site Ref # / Investigator 494
    Wichita, Kansas 67208, United States
  • Site Ref # / Investigator 491
    Lexington, Kentucky 40509, United States
  • Site Ref # / Investigator 2508
    Portland, Maine 04102, United States
  • Site Ref # / Investigator 392
    Baltimore, Maryland 21239, United States
  • Site Ref # / Investigator 354
    Cumberland, Maryland 21502, United States
  • Site Ref # / Investigator 730
    Wheaton, Maryland 20902, United States
  • Site Ref # / Investigator 465
    Burlington, Massachusetts 01805, United States
  • Site Ref # / Investigator 2512
    Worcester, Massachusetts 01610, United States
  • Site Ref # / Investigator 471
    Grand Rapids, Michigan 49506, United States
  • Site Ref # / Investigator 473
    Kalamazoo, Michigan 49009, United States
  • Site Ref # / Investigator 731
    Kansas City, Missouri 64114, United States
  • Site Ref # / Investigator 502
    St. Louis, Missouri 63110, United States
  • Site Ref # / Investigator 482
    St. Louis, Missouri 63128, United States
  • Site Ref # / Investigator 371
    St. Louis, Missouri 63141, United States
  • Site Ref # / Investigator 487
    Omaha, Nebraska 68114, United States
  • Site Ref # / Investigator 353
    Concord, New Hampshire 03301, United States
  • Site Ref # / Investigator 364
    Dover, New Hampshire 03820, United States
  • Site Ref # / Investigator 60726
    Mercerville, New Jersey 08619, United States
  • Site Ref # / Investigator 358
    Voorhees, New Jersey 08043, United States
  • Site Ref # / Investigator 483
    Rochester, New York 14609, United States
  • Site Ref # / Investigator 512
    Durham, North Carolina 27704, United States
  • Site Ref # / Investigator 340
    Greensboro, North Carolina 27408, United States
  • Site Ref # / Investigator 461
    Raleigh, North Carolina 27609, United States
  • Site Ref # / Investigator 500
    Raleigh, North Carolina 27609, United States
  • Site Ref # / Investigator 60731
    Raleigh, North Carolina 27612, United States
  • Site Ref # / Investigator 60737
    Salisbury, North Carolina 28144, United States
  • Site Ref # / Investigator 456
    Mayfield Village, Ohio 44143, United States
  • Site Ref # / Investigator 470
    Oklahoma City, Oklahoma 73112, United States
  • Site Ref # / Investigator 60723
    Oklahoma, Oklahoma 73112, United States
  • Site Ref # / Investigator 422
    Eugene, Oregon 97401, United States
  • Site Ref # / Investigator 60735
    Colmar, Pennsylvania 18915-9671, United States
  • Site Ref # / Investigator 2507
    Duncansville, Pennsylvania 16635, United States
  • Site Ref # / Investigator 717
    East Norriton, Pennsylvania 19401, United States
  • Site Ref # / Investigator 352
    Mechanicsburg, Pennsylvania 17055, United States
  • Site Ref # / Investigator 480
    Wexford, Pennsylvania 15090, United States
  • Site Ref # / Investigator 2511
    Wyomissing, Pennsylvania 19610, United States
  • Site Ref # / Investigator 60724
    Wyomissing, Pennsylvania 19610, United States
  • Site Ref # / Investigator 718
    Charleston, South Carolina 29406, United States
  • Site Ref # / Investigator 460
    Memphis, Tennessee 38119, United States
  • Site Ref # / Investigator 462
    Nashville, Tennessee 37205, United States
  • Site Ref # / Investigator 716
    Austin, Texas 78705, United States
  • Site Ref # / Investigator 60728
    Galveston, Texas 77555-0759, United States
  • Site Ref # / Investigator 2509
    Houston, Texas 77074, United States
  • Site Ref # / Investigator 510
    Houston, Texas 77074, United States
  • Site Ref # / Investigator 60725
    Falls Church, Virginia 22044, United States
  • Site Ref # / Investigator 711
    Richmond, Virginia 23219, United States
  • Site Ref # / Investigator 509
    Seattle, Washington 98166-2967, United States
  • Site Ref # / Investigator 356
    Spokane, Washington 99204, United States
  • Site Ref # / Investigator 464
    Tacoma, Washington 98405, United States
  • Site Ref # / Investigator 60738
    Kenosha, Wisconsin 53142, United States
  • Site Ref # / Investigator 475
    Calgary, Alberta T2N 4N1, Canada
  • Site Ref # / Investigator 495
    Penticton, British Columbia V2A 3G8, Canada
  • Site Ref # / Investigator 2496
    Richmond, British Columbia V7C 5L9, Canada
  • Site Ref # / Investigator 2495
    Winnipeg, Manitoba R3N OK6, Canada
  • Site Ref # / Investigator 496
    Halifax, Nova Scotia B3H 4K4, Canada
  • Site Ref # / Investigator 444
    Newmarket, Ontario L3Y 3R7, Canada
  • Site Ref # / Investigator 2497
    Toronto, Ontario M4N 3M5, Canada
  • Site Ref # / Investigator 478
    Toronto, Ontario M5L 3L9, Canada
  • Site Ref # / Investigator 421
    Toronto, Ontario M5T 2S8, Canada
  • Site Ref # / Investigator 363
    Montreal, Quebec H3Z 2Z3, Canada
  • Site Ref # / Investigator 60702
    Saskatoon, Saskatchewan S7N 0W8, Canada
09

References and documents

Publications

  • Smolen J, Fleischmann R, Aletaha D, Li Y, Zhou Y, Sainsbury I, Galindo IL. Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Res Ther. 2019 Nov 10;21(1):231. doi: 10.1186/s13075-019-2005-9. PubMed 31707982 ↗
  • Keystone EC, Breedveld FC, van der Heijde D, van Vollenhoven RF, Emery P, Smolen JS, Sainsbury I, Florentinus S, Kupper H, Chen K, Kavanaugh A. Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. RMD Open. 2017 Sep 26;3(2):e000445. doi: 10.1136/rmdopen-2017-000445. eCollection 2017. PubMed 29018564 ↗
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Emery P, Kavanaugh A, Bao Y, Ganguli A, Mulani P. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis? Ann Rheum Dis. 2015 Dec;74(12):2165-74. doi: 10.1136/annrheumdis-2014-205302. Epub 2014 Aug 19. PubMed 25139667 ↗
  • Landewe R, Ostergaard M, Keystone EC, Florentinus S, Liu S, van der Heijde D. Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2015 Feb;67(2):180-6. doi: 10.1002/acr.22426. PubMed 25073879 ↗
  • Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, Mozaffarian N. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol. 2013 Sep;40(9):1487-97. doi: 10.3899/jrheum.120964. Epub 2013 Jul 1. PubMed 23818718 ↗
  • Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL. Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. J Rheumatol. 2011 May;38(5):855-62. doi: 10.3899/jrheum.100752. Epub 2011 Feb 1. PubMed 21285171 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2000, a primary completion of Sep 2002 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 7 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Feb 2000
Primary completionActual
Sep 2002
CompletionActual
Aug 2010
Results first posted
Mar 1, 2010
Last update
Aug 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195702
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Feb 2000
Primary completion
Sep 2002
Completion
Aug 2010
Results posted
Mar 1, 2010
Last update
Aug 26, 2011

Study contacts

Laura Redden, MD, PhD
study director · Abbott

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion